MXPA05006940A - Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. - Google Patents

Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.

Info

Publication number
MXPA05006940A
MXPA05006940A MXPA05006940A MXPA05006940A MXPA05006940A MX PA05006940 A MXPA05006940 A MX PA05006940A MX PA05006940 A MXPA05006940 A MX PA05006940A MX PA05006940 A MXPA05006940 A MX PA05006940A MX PA05006940 A MXPA05006940 A MX PA05006940A
Authority
MX
Mexico
Prior art keywords
related diseases
agent
treatment
beta
therapeutic formulations
Prior art date
Application number
MXPA05006940A
Other languages
English (en)
Spanish (es)
Inventor
Francesco Bellini
Original Assignee
Neurochem Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem Int Ltd filed Critical Neurochem Int Ltd
Publication of MXPA05006940A publication Critical patent/MXPA05006940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
MXPA05006940A 2002-12-24 2003-12-24 Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. MXPA05006940A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43637902P 2002-12-24 2002-12-24
US48221403P 2003-06-23 2003-06-23
PCT/CA2003/002011 WO2004058258A1 (en) 2002-12-24 2003-12-24 Therapeutic formulations for the treatment of beta-amyloid related diseases

Publications (1)

Publication Number Publication Date
MXPA05006940A true MXPA05006940A (es) 2006-02-22

Family

ID=32685452

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006940A MXPA05006940A (es) 2002-12-24 2003-12-24 Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.

Country Status (13)

Country Link
US (1) US20060135403A1 (https=)
EP (2) EP1585520A1 (https=)
JP (2) JP2006525226A (https=)
KR (1) KR20050101537A (https=)
AU (2) AU2003292936A1 (https=)
BR (1) BR0317747A (https=)
CA (2) CA2511599A1 (https=)
EA (1) EA012325B1 (https=)
IL (1) IL169338A0 (https=)
MX (1) MXPA05006940A (https=)
NO (1) NO20053077L (https=)
NZ (1) NZ541282A (https=)
WO (2) WO2004058239A1 (https=)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2525970C (en) 2003-05-15 2011-03-22 Roskamp Research, Llc Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
EP1646375A2 (en) * 2003-06-23 2006-04-19 Neurochem (International) Limited Treatment of protein aggregation disorders
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP5146714B2 (ja) * 2003-06-23 2013-02-20 ビーエイチアイ リミテッド パートナーシップ アミロイド関連疾患を治療するための方法および組成物
EP1661881B1 (en) * 2003-08-29 2014-12-17 Ono Pharmaceutical Co., Ltd. Compound capable of binding s1p receptor and pharmaceutical use thereof
EP2336147B1 (en) 2003-12-17 2014-04-30 Janssen Alzheimer Immunotherapy A beta immunogenic peptide carrier conjugates and methods of producing same
MXPA06011969A (es) * 2004-04-14 2006-12-15 Warner Lambert Co Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.
EP1841460A2 (en) * 2004-06-18 2007-10-10 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
JP4717537B2 (ja) * 2004-08-31 2011-07-06 株式会社 資生堂 皮膚外用組成物
US20060183800A1 (en) * 2004-11-12 2006-08-17 Xianqi Kong Methods and fluorinated compositions for treating amyloid-related diseases
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US7420071B2 (en) * 2005-05-04 2008-09-02 Uchicago Argonne, Llc Thermally stable surfactants and compositions and methods of use thereof
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
CA2633399C (en) 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
EP1968561B8 (en) 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
CA2675230A1 (en) * 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
LT2468770T (lt) 2006-07-14 2018-05-25 Ac Immune S.A. Humanizuotas antikūnas prieš beta amiloidą
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
CN102838532A (zh) 2006-11-24 2012-12-26 Ac免疫有限公司 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
EP2160352A2 (en) * 2007-05-24 2010-03-10 Simone Arca Method for the production of binary clathrate hydrates of hydrogen
PL2170389T3 (pl) 2007-06-12 2015-03-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
EP2527366B1 (en) 2007-06-12 2017-08-16 AC Immune S.A. Monoclonal anti beta amyloid antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2182978A4 (en) 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
TWI500422B (zh) 2007-10-05 2015-09-21 Alzheimer S Inst Of America Inc 以（－）－尼代地平（ｎｉｌｖａｄｉｐｉｎｅ）對映異構物減低類澱粉沉積、類澱粉神經毒性及微神經膠細胞增生之方法
SG178809A1 (en) 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
WO2009059239A2 (en) * 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
WO2010042603A1 (en) * 2008-10-08 2010-04-15 Cingulate Neuro Therapeutics, Llc Amyloid and depression
SI2408807T1 (sl) 2009-03-18 2021-11-30 Ac Immune Sa Postopek za terapevtsko uporabo
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
JP5051274B2 (ja) * 2009-06-04 2012-10-17 住友化学株式会社 加硫ゴムが有する粘弾性特性を改善させるためのｓ−（３−アミノプロピル）チオ硫酸および／またはその金属塩の使用
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
PH12012502079A1 (en) 2010-04-16 2013-02-11 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
EP2377860A1 (en) 2010-04-16 2011-10-19 AC Immune S.A. Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
ES2548686T3 (es) 2010-10-07 2015-10-20 Ac Immune S.A. Anticuerpos que reconocen fosfo-Tau
AR083561A1 (es) 2010-10-26 2013-03-06 Ac Immune Sa Preparacion de una construccion antigenica
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
US9499488B2 (en) * 2011-07-11 2016-11-22 Beth Israel Deaconess Medical Center, Inc. Vitamin D receptor agonists and uses thereof
KR102129220B1 (ko) 2011-09-23 2020-07-02 에이씨 이뮨 에스.에이. 백신 요법
RU2639537C2 (ru) 2011-10-07 2017-12-21 Ац Иммуне С.А. Фосфоспецифичные антитела, распознающие тау
JP6293731B2 (ja) 2012-04-05 2018-03-14 エーシー イミューン エス．エー． ヒト化タウ抗体
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
CA2881464C (en) * 2012-08-07 2021-12-21 Children's Medical Center Corporation Potassium channel openers for treating neurodegenerative diseases
GEP201706739B (en) * 2012-12-13 2017-09-25 H Lundbeck As Compositions comprising vortioxetine and donepezil
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
CN105143258B (zh) 2013-03-15 2020-06-23 Ac免疫有限公司 抗Tau抗体和使用方法
WO2015110263A1 (en) 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
US10314911B2 (en) * 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
AU2014393490B2 (en) * 2014-05-09 2020-01-02 Tecnimede Sociedade Tecnico-Medicinal S.A. (S)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX368735B (es) * 2014-05-09 2019-10-14 Tecnimede Sociedade Tecnico Medicinal S (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
SI3221349T1 (sl) 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
EP4465050A3 (en) 2015-06-05 2025-06-11 Genentech, Inc. Anti-tau antibodies and methods of use
JP6928385B2 (ja) 2015-08-10 2021-09-01 アルジオン， インコーポレイテッド 神経変性疾患を治療および予防するための組成物および方法
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004494A1 (en) 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
ITUA20161679A1 (it) 2016-03-15 2017-09-15 Neuraxpharm Italy S P A Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US11970521B2 (en) 2016-08-20 2024-04-30 Arizona Board Of Regents On Behalf Of The University Of Arizona Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
MA48595A (fr) 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
CN117820467A (zh) 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
KR20190133162A (ko) 2017-03-28 2019-12-02 제넨테크, 인크. 신경퇴행성 질병의 치료 방법
WO2018200381A1 (en) * 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
KR101917128B1 (ko) 2017-04-28 2018-11-09 강원대학교산학협력단 산양삼 추출물을 포함하는 알츠하이머병의 예방 또는 치료용 약학 조성물
WO2019018445A1 (en) * 2017-07-17 2019-01-24 Maxwell Biosciences, Inc. POLYTHERAPY MODULATING THE MODULATION OF CATHELICIDINE GENE EXPRESSION FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
WO2019074840A1 (en) * 2017-10-09 2019-04-18 Keith Black COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
KR102710762B1 (ko) 2017-10-25 2024-09-25 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
PE20211090A1 (es) 2018-01-05 2021-06-14 Ac Immune Sa Derivados de 1,3,4,5-tetrahidro-2h-pirido[4,3-b]indol para el tratamiento, alivio o prevencion de trastornos asociados con los agregados de tau
WO2019186276A2 (en) 2018-03-28 2019-10-03 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
CN112313230B (zh) 2018-06-04 2024-03-15 Ac免疫有限公司 用于治疗、缓解或预防与Tau聚集体相关的病症的新型化合物
EA202092557A1 (ru) 2018-06-04 2021-04-01 Ас Иммьюн Са СОЕДИНЕНИЯ ТЕТРАГИДРОБЕНЗОФУРО[2,3-c]ПИРИДИНА И БЕТА-КАРБОЛИНА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ-БЕЛКА
KR20200086198A (ko) 2019-01-08 2020-07-16 주식회사 솔고 바이오메디칼 수소 흡장 금속을 포함하는 치매 예방 또는 치료용 조성물
WO2020150423A1 (en) * 2019-01-16 2020-07-23 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
AU2020219804A1 (en) 2019-02-08 2021-08-19 Ac Immune S.A. Method of safe administration of phosphorylated Tau peptide vaccine
JP7232931B2 (ja) 2019-03-01 2023-03-03 エイシー イミューン ソシエテ アノニム タウ凝集体に関連する障害の治療、緩和、または予防のための新規化合物
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
JP7327788B2 (ja) * 2019-08-06 2023-08-16 学校法人福岡大学 糖化産物生成抑制剤及び医薬組成物
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
WO2021067850A2 (en) * 2019-10-02 2021-04-08 Washington University METHODS OF DETECTING circRNA
ES2821599A1 (es) 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
CN112939823A (zh) * 2019-12-10 2021-06-11 中国石油天然气股份有限公司 泥页岩抑制剂制备方法及抑制剂的应用
KR20210133603A (ko) 2020-04-29 2021-11-08 정지영 굼벵이를 포함하는 치매 예방 또는 치료용 조성물
US20210353566A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology The use of choline supplementation as therapy for apoe4-related disorders
AR123730A1 (es) 2020-10-15 2023-01-04 Ac Immune Sa Compuestos novedosos
JP7682515B2 (ja) * 2020-12-11 2025-05-26 国立研究開発法人国立長寿医療研究センター 認知症の危険性判定システムおよび認知症の危険性判定用プログラム
KR102598904B1 (ko) * 2022-12-16 2023-11-06 닥터노아바이오텍 주식회사 콜린에스터라제 억제제의 부작용 예방 또는 치료용 조성물
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
CN115624555A (zh) * 2022-02-24 2023-01-20 中国药科大学 猪去氧胆酸在制备抗抑郁药物中的应用
EP4494141A1 (en) 2022-03-14 2025-01-22 Genentech, Inc. Predicting neurodegenerative diseases based on speech analyses
KR20230147988A (ko) * 2022-04-15 2023-10-24 아주대학교산학협력단 Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물
EP4544544A1 (en) 2022-06-21 2025-04-30 Genentech Inc. Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses
WO2026037826A1 (en) 2024-08-12 2026-02-19 Ac Immune Sa 2,4-dihydropyrazolo[3',4':4,5]pyrano[2,3-b]pyridine compounds
CN119570766B (zh) * 2025-02-08 2025-05-16 上海锴泰生物科技有限公司 一种胶原蛋白酶突变体、基因片段、重组质粒、重组表达体系、胶原蛋白肽，及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434571T2 (de) * 1993-03-29 2006-08-03 Queen's University At Kingston, Kingston Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
WO1997021728A1 (en) * 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
JPH10259126A (ja) * 1997-01-17 1998-09-29 Takeda Chem Ind Ltd アルツハイマー病治療・予防剤
WO1999040909A1 (en) * 1998-02-11 1999-08-19 Neurochem, Inc. Method for modulating macrophage activation
GB9805561D0 (en) * 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
WO1999059571A1 (en) * 1998-05-15 1999-11-25 Neurochem, Inc. Use of amyloid inhibitors for modulating neuronal cell death
EP1161449B1 (en) * 1999-03-04 2007-07-04 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising d-amino acids
CA2369997C (en) * 1999-04-28 2009-11-17 Queen's University At Kingston Compositions and methods for treating amyloidosis
WO2000068263A2 (en) * 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
IL150374A0 (en) * 1999-12-23 2002-12-01 Neurochem Inc Compounds and methods for modulating cerebral amyloid angiopathy
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
US20040072753A1 (en) * 2000-11-01 2004-04-15 Milton Nathaniel Gavin Nicolas Peptides for use in the treatment of alzheimer's disease
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20050038000A1 (en) * 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof

Also Published As

Publication number Publication date
AU2003291910B2 (en) 2009-10-01
WO2004058239A1 (en) 2004-07-15
CA2511599A1 (en) 2004-07-15
EP1581203A1 (en) 2005-10-05
JP2006512417A (ja) 2006-04-13
EA012325B1 (ru) 2009-08-28
WO2004058258A1 (en) 2004-07-15
NO20053077D0 (no) 2005-06-23
NZ541282A (en) 2009-02-28
EA200501023A1 (ru) 2005-12-29
AU2003291910A1 (en) 2004-07-22
NO20053077L (no) 2005-09-22
CA2511606A1 (en) 2004-07-15
JP2006525226A (ja) 2006-11-09
US20060135403A1 (en) 2006-06-22
KR20050101537A (ko) 2005-10-24
IL169338A0 (en) 2007-07-04
BR0317747A (pt) 2005-11-22
EP1585520A1 (en) 2005-10-19
AU2003292936A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
IL139230A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds to the upper respiratory tract and/or the ear
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
EP1458734A4 (en) ISOINDIGO, INDIGO AND INDIRUBIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
GB0130677D0 (en) Medicaments and novel compounds
WO2002014343A8 (en) Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
DE60119976D1 (en) Thixotropes nasenspray
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
DE60005952D1 (de) Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration
IL110888A0 (en) Pharmaceutical compositions for the treatment of liver diseases comprising a benzothiazepine derivative
WO2003066806A3 (en) Therapeutic use of aziridino compounds

Legal Events

Date Code Title Description
FG Grant or registration